A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry.

  title={A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry.},
  author={Dimple Pabla and Fatemeh Akhlaghi and Hossein Zia},
  journal={European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V},
  volume={72 1},
  • Dimple Pabla, F. Akhlaghi, H. Zia
  • Published 1 May 2009
  • Chemistry
  • European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Figures and Tables from this paper

In vivo dissolution of levothyroxine soft gel capsules

The in vitro dissolution time of the new soft gel capsules formulation is compared with its in vivo behaviour that has been observed during a gastroscopy performed on a healthy volunteer and confirms what was already known in vitro: the total dissolved time of a soft gel capsule is about 20 min, and the dissolution profile is not pH dependent.

Effect of batch age on potency and dissolution of levothyroxine sodium tablets: impact of BP and USP monograph differences on dissolution results

Generated potency values indicated the prevalence of super-potent tablet batches and dissolution data reflected the effect of compendia monograph differences in dissolution medium indicated an inverse relationship between tablet potency and batch age and, between dissolution andbatch age.

An Investigation into the Influence of Experimental Conditions on In Vitro Drug Release from Immediate-Release Tablets of Levothyroxine Sodium and Its Relation to Oral Bioavailability

The study results indicate that the current regulatory criteria for the value of similarity factor in comparative dissolution testing, as well as request for very rapid dissolution, are very restricted for immediate-release dosage forms containing highly soluble drug substance and need further investigation.

In Vitro–In Vivo Correlation of Efavirenz Tablets Using GastroPlus®

The simulation of gastrointestinal bioavailability and IVIVC obtained from immediate-release tablet formulations suggests that GastroPlus™ is a valuable in silico method for IVIVCs and for studies directed at developing formulations of class II drugs.

Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule

Levothyroxine oral solution unit‐dose ampules were bioequivalent to the levothyroxin capsule when administered with or without water, and all formulations were well tolerated, with no major side effects.

Development of a Discriminative Intrinsic Dissolution Method for Efavirenz

The developed intrinsic dissolution method may be used in the development of efavirenz formulations to select API with physical–chemical properties that enable appropriate dosage form dissolution.

Capecitabine: An In-vitro Comparison between the Branded Xeloda ® 500 Mg and its Intended Copy Capeda 500 Mg

Results in this study clearly raise a question about the interchangeability between Xeloda® 500 mg and its Intended copy Capeda 500 mg.

A case study on the in silico absorption simulations of levothyroxine sodium immediate‐release tablets

The obtained results suggest that dissolution specification of more than 85% LT4 dissolved in 60 min might be considered as biorelevant dissolution specification criteria for LT4 IR tablets.



Multiple level C in vitro/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism.

Development and validation of an inductively coupled plasma mass spectrometry method for quantification of levothyroxine in dissolution studies.

The ICP-MS method has successfully been used for dissolution studies of T4 formulations and holds immense promise as a simple, precise and sensitive analytical technique for T4 concentration determination in in vitro studies.


This study cannot support a recommendation to substitute levothyroxine products without careful retesting and retitration, and indicates that interchange of therapeutically inequivalent products may result in over‐ or under‐replacement of thyroid hormone, with the known potential adverse consequences.

Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?

The methodology that the Food and Drug Administration recommends for comparing the bioavailability of LT4 products, as well as three modifications to correct for endogenous, thyroxine (T4) levels, were examined to determine if the methodology could distinguishLT4 products that differ by 12.5%, 25%, or 33%.

Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate

The current recommended methodology in the United States to assess bioequivalence for levothyroxine sodium products is inadequate to differentiate products that differ by 12.5%, a clinically relevant difference.

Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease.

  • I. KleinS. Danzi
  • Medicine, Biology
    Thyroid : official journal of the American Thyroid Association
  • 2003
The various methods to evaluate therapeutic efficacy and bioequivalence of levothyroxine preparations in the treatment of thyroid disease are discussed.

Levothyroxine: therapeutic use and regulatory issues related to bioequivalence

  • L. Wartofsky
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2002
The basis for concern about currently accepted standards of the FDA for pharmacological bioequivalence are examined in the context of levothyroxine.

Kinetics of Degradation of Levothyroxine in Aqueous Solution and in Solid State

  • C. M. Won
  • Chemistry
    Pharmaceutical Research
  • 2004
The solid-state stability of levothyroxine sodium was studied at elevated temperatures; and the compound was found to undergo deamination on heating, with the most rapid decomposition occurring at the beginning of heating.

Standards for levothyroxine preparations.

It is demonstrated that the 100-μg tablets from Letter and Synthroid were physiologically nonbioequivalent and therefore should not be dispensed interchangeably and therefore the current USP recognizes the effect of particle size on bioavailability.

Effect of solvent type on the determination of total iodine in milk powder and human serum by inductively coupled plasma mass spectrometry.

It is shown that the oxidation state of the analyte has a strong impact on the analytical performance, and as the iodine in milk powder is present almost exclusively as iodide, destruction of the sample with nitric acid is not suitable.